Therapeutic Indications

Bendamustine is indicated for:

Multiple myeloma

Irrespective of gender only Adults (18 years old or older)

Front line treatment of multiple myeloma (Durie-Salmon stage II with progress or stage III) in combination with prednisone for patients older than 65 years who are not eligible for autologous stem cell transplantation and who have clinical neuropathy at time of diagnosis precluding the use of thalidomide or bortezomib containing treatment.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 120-150 mg/m² once a day for 2 days

Non-Hodgkin's lymphomas

Irrespective of gender only Adolescents (12 years - 18 years old) Adults (18 years old or older)

Indolent non-Hodgkin’s lymphomas as monotherapy in patients who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 120 mg/m² once a day for 2 days

Chronic lymphocytic leukaemia

Irrespective of gender only Adolescents (12 years - 18 years old) Adults (18 years old or older)

First-line treatment of chronic lymphocytic leukaemia (Binet stage B or C) in patients for whom fludarabine combination chemotherapy is not appropriate.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 100 mg/m² once a day for 2 days

Contraindications

Active ingredient Bendamustine is contraindicated in the following cases:

Lactation

No gender/age discrimination

It is not known whether bendamustine passes into the breast milk, therefore, bendamustine is contraindicated during breast-feeding. Breast-feeding must be discontinued during treatment with bendamustine.